Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10653743
Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
granted -
US 10647964
Non-neuroinvasive viruses and uses thereof
granted -
US 10646593
Activatable membrane-interacting peptides and methods of use
granted -
US 10649053
Cardiac late gadolinium enhancement MRI for patients with implanted cardiac devices
granted -
US 10647658
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
granted -
US 10646574
Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
granted -
US 10646577
mTORC1 inhibitors
granted -
US 10646438
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
granted -
US 10646555
Compositions and methods relating to argininosuccinate synthetase
granted -
US 10639277
Multi-functional echogenic immunoliposomes for directed stem cell delivery to atheroma
granted -
US 10639302
Use of CDK9 inhibitors to reduce cartilage degradation
granted -
US 10640570
Chimeric antigen receptors, compositions, and methods
granted -
US 10640791
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10640493
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
granted -
US 10639357
Enzymes and methods for cleaving N-glycans from glycoproteins
granted -
US 10640535
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
granted -
US 10633643
Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
granted -
US 10633344
Multiple-component solid phases containing at least one active pharmaceutical ingredient
granted -
US 10632152
Chimeric antigen receptor and methods of use thereof
granted -
US 10632070
Hydrogel toxin-absorbing or binding nanoparticles
granted -
US 10633386
BET protein degraders
granted -
US 10633411
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
granted -
US 10632211
Demethylation to treat eye disease
granted -
US 10633657
Methods for treatment of polycystic kidney disease
granted -
US 10633445
T-cell receptor (TCR)-binding antibodies and uses thereof
granted -
US 10633432
VC-CAR molecule and use thereof in removing HIV-1 infected cells
granted -
US 10633370
Phenyl indole allosteric inhibitors of p97 ATPase
granted -
US 10632209
ASH1L inhibitors and methods of treatment therewith
granted -
US 10633442
Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening
granted -
US 10633363
EPAC1 activators as HIV latency reversal agents (LRA)
granted -
US 10632180
Methods and compositions for improved cognition
granted -
US 10626469
Rapid identification of microorganisms
granted -
US 10626145
Peptide with anti-obesity and anti-diabetes activity and use thereof
granted -
US 10626419
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10627409
Therapeutic antibodies against ROR-1 protein and methods for use of same
granted -
US 10624959
Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
granted -
US 10626087
Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same
granted -
US 10617757
Methods for treating multiple myeloma
granted -
US 10620204
Antibody-mediated neutralization of Ebola viruses
granted -
US 10618983
Hyaluronic acid-based hydrogels having medical applications
granted -
US 10617709
miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
granted -
US 10619153
TAL effector-mediated DNA modification
granted -
US 10618972
Antibodies for botulinum neurotoxins
granted -
US 10619156
Hybrid tRNA/pre-miRNA molecules and methods of use
granted -
US 10617740
Methods of treating mild brain injury
granted -
US 10617706
Compounds for cancer chemotherapeutic sensitization
granted -
US 10618869
Oligo-benzamide compounds and their use
granted -
US 10617667
Method for treating brain tumors
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory